News for Compass Therapeutics, Inc. (CMPX)

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the top high-return penny stocks to buy now. On July 14, Stifel reiterated its Buy rating and $11.00 price target for CMPX. The firm views the extended timeline for topline data from the Phase 2/3 COMPANION-002 trial—now expected in Q4 2025—as a positive, given the 19-month follow-up in […]

A virtual meeting is scheduled for June 13, with Piper Sandler as the host, featuring CMPX. This event will provide insights into the company's strategies and p

Compass Therapeutics' tovecimig shows promise in biliary cancer, boasting a 17.1% response rate. Despite high risks, I maintain a Buy on CMPX. See more here.

On May 9, 2025, Compass Therapeutics (CMPX) saw its price target adjusted by Guggenheim. Analyst Michael Schmidt maintained a 'Buy' rating on CMPX but lowered t

Guggenheim has revised its price target for Compass Therapeutics (CMPX), reducing it from $12 to $10 while maintaining a Buy rating. Following the company's lat

BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. ( CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprieta

Compass Therapeutics (CMPX) has commenced a new Investigator Sponsored Trial (IST) with the dosing of the first patient to assess tovecimig as a primary treatme

BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. ( CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprie

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. ( CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprie

**media[582593]**

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Compass Therapeutics, Inc.

Net Loss: Reported a net loss of $49.4 million for 2024, compared to $42.5 million in 2023, reflecting increased investment in R&D.Earnings Per Share (EPS): Re

Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (B

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Explore Compass Therapeutics' tovecimig trials, upcoming Phase 3 BTC data, and market insights.

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiation...

On December 31, 2024, MPM BIOIMPACT LLC (Trades, Portfolio)executed a significant transaction involving Compass Therapeutics Inc. The firm added 2,926,002 shar

On December 31, 2024, ADAGE CAPITAL PARTNERS GP, L.L.C. (Trades, Portfolio) executed a notable transaction involving Compass Therapeutics Inc (CMPX). The firm r

Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).